Risk factors for drug hypersensitivity reactions in children.

Humans Risk Factors Child Drug Hypersensitivity / diagnosis
Children Drug allergy Hypersensitivity reactions Risk factors Severe cutaneous adverse reaction

Journal

Italian journal of pediatrics
ISSN: 1824-7288
Titre abrégé: Ital J Pediatr
Pays: England
ID NLM: 101510759

Informations de publication

Date de publication:
15 Jul 2024
Historique:
received: 04 04 2024
accepted: 25 06 2024
medline: 16 7 2024
pubmed: 16 7 2024
entrez: 15 7 2024
Statut: epublish

Résumé

Drug hypersensitivity reactions are common in children. Risk factors predisposing to IgE-mediated drug allergies and delayed drug reactions are a matter of debate. Gender, age, previous reactions to the same drug or to another drug, reduced drug metabolism, chronic diseases, polypharmacy, drug doses are linked with the onset of hypersensitivity reactions in some children. Novel advances in genetic polymorphisms can rapidly change the approach to the prevention of reactions since gene testing can be a useful screening test for severe cutaneous adverse reactions. Viral infections may act as cofactors in susceptible individuals. Polypharmacy, high doses, repeated doses and parental route of administration are also risk factors. Clinicians should take into account risk factors to allow the risk-benefit balance to be maintained.

Identifiants

DOI: 10.1186/s13052-024-01694-x PMID: 39010141
pubmed: 39010141
doi: 10.1186/s13052-024-01694-x
pii: 10.1186/s13052-024-01694-x
doi:

Types de publication

Journal Article Review

Langues

eng

Sous-ensembles de citation

IM

Pagination

127

Informations de copyright

© 2024. The Author(s).

Références

Gallagher RM, Bird KA, Mason JR, Peak M, Williamson PR, Nunn AJ, et al. Adverse drug reactions causing admission to a paediatric hospital: a pilot study. J Clin Pharm Ther. 2011;36:194–9.
pubmed: 21366649 doi: 10.1111/j.1365-2710.2010.01194.x
Cousin M, Chiriac A, Molinari N, Demoly P, Caimmi D. Phenotypical characterization of children with hypersensitivity reactions to NSAIDs. Pediatr Allergy Immunol. 2016;27:743–8.
pubmed: 27171669 doi: 10.1111/pai.12596
Rieder M. New ways to detect adverse drug reactions in pediatrics. Pediatr Clin North Am. 2012;59:1071–92.
pubmed: 23036245 doi: 10.1016/j.pcl.2012.07.010
Hanschmann T, Francuzik W, Dölle-Bierke S, Hofmeier KS, Grabenhenrich L, Ruëff F, et al. Different phenotypes of drug-induced anaphylaxis-Data from the European Anaphylaxis Registry. Allergy. 2023;78:1615–27.
pubmed: 36479710 doi: 10.1111/all.15612
Gomes ER, Brockow K, Kuyucu S, Saretta F, Mori F, Blanca-Lopez N, et al. Drug hypersensitivity in children: report from the pediatric task force of the EAACI Drug Allergy Interest Group. Allergy. 2016;71:149–61.
pubmed: 26416157 doi: 10.1111/all.12774
Kidon MI, See Y. Adverse drug reactions in Singaporean children. Singapore Med J. 2004;45:574–7.
pubmed: 15568118
Rebelo Gomes E, Geraldes L, Gaspar Â, Malheiro D, Cadinha S, Abreu C, et al. Hypersensitivity reactions to nonsteroidal anti-inflammatory drugs among adults: Clinical features and risk factors for diagnosis confirmation. Int Arch Allergy Immunol. 2016;171:269–75.
pubmed: 28049210 doi: 10.1159/000452627
Stepanovic B, Sommerfield D, Lucas M, von Ungern-Sternberg BS. An update on allergy and anaphylaxis in pediatric anesthesia. Paediatr Anaesth. 2019;29:892–900.
pubmed: 31379063 doi: 10.1111/pan.13703
Park JS, Suh DI. Drug allergy in children: what should we know? Clin Exp Pediatr. 2020;63:203–10.
pubmed: 32024327 doi: 10.3345/kjp.2019.00675
Rieder M. Adverse Drug Reactions in Children: Pediatric Pharmacy and Drug Safety. J Pediatr Pharmacol Ther. 2019;24:4–9.
pubmed: 30837807 pmcid: 6397008
Guvenir H, Dibek Misirlioglu E, Civelek E, Toyran M, Buyuktiryaki B, Ginis T, et al. The frequency and clinical features of hypersensitivity reactions to antiepileptic drugs in children: A prospective study. J Allergy Clin Immunol Pract. 2018;6:2043–50.
pubmed: 29501520 doi: 10.1016/j.jaip.2018.02.018
Anderson GD. Children versus adults: pharmacokinetic and adverse-effect differences. Epilepsia. 2002;43(Suppl 3):53–9.
pubmed: 12060006 doi: 10.1046/j.1528-1157.43.s.3.5.x
Hirsch LJ, Weintraub DB, Buchsbaum R, Spencer HT, Straka T, Hager M, et al. Predictors of Lamotrigine-associated rash. Epilepsia. 2006;47:318–22.
pubmed: 16499755 doi: 10.1111/j.1528-1167.2006.00423.x
Kearns GL, Wheeler JG, Rieder MJ, Reid J. Serum sickness-like reaction to cefaclor: lack of in vitro cross-reactivity with loracarbef. Clin Pharmacol Ther. 1998;63:686–93.
pubmed: 9663184 doi: 10.1016/S0009-9236(98)90093-5
Menniti-Ippolito G, Raschetti R, Da Cas R, Giaquinto C, Cantarutti L. Active monitoring of adverse drug reactions in children. Italian Paediatric Pharmacosurveillance Multicenter Group Lancet. 2000;355:1613–4.
pubmed: 10821367
Sánchez-Borges M, Capriles-Behrens E, Caballero-Fonseca F. Hypersensitivity to non-steroidal anti-inflammatory drugs in childhood. Pediatr Allergy Immunol. 2004;15:376–80.
pubmed: 15305949 doi: 10.1111/j.1399-3038.2004.00159.x
Kidon M, Blanca-Lopez N, Gomes E, Terreehorst I, Tanno L, Ponvert C, et al. EAACI/ENDA Position Paper: Diagnosis and management of hypersensitivity reactions to non-steroidal anti-inflammatory drugs (NSAIDs) in children and adolescents. Pediatr Allergy Immunol. 2018;29:469–80.
pubmed: 29693290 doi: 10.1111/pai.12915
Mori F, Saretta F, Bianchi A, Crisafulli G, Caimmi S, Liotti L, et al. Hypersensitivity Reactions to Monoclonal Antibodies in Children. Medicina (Kaunas). 2020;56:232.
pubmed: 32408641 doi: 10.3390/medicina56050232
Dias de Castro E, Carolino F, Carneiro-Leão L, Barbosa J, Ribeiro L, Cernadas JR. Allergy to beta-lactam antibiotics in children: Risk factors for a positive diagnostic work-up. Allergol Immunopathol (Madr). 2020;48:417–23.
Arikoglu T, Aslan G, Batmaz SB, Eskandari G, Helvaci I, Kuyucu S. Diagnostic evaluation and risk factors for drug allergies in children: from clinical history to skin and challenge tests. Int J Clin Pharm. 2015;37:583–91.
pubmed: 25822038 doi: 10.1007/s11096-015-0100-9
Faitelson Y, Boaz M, Dalal I. Asthma, Family History of Drug Allergy, and Age Predict Amoxicillin Allergy in Children. J Allergy Clin Immunol Pract. 2018;6:1363–7.
pubmed: 29226807 doi: 10.1016/j.jaip.2017.11.015
Co Minh H-B, Bousquet PJ, Fontaine C, Kvedariene V, Demoly P. Systemic reactions during skin tests with beta-lactams: a risk factor analysis. J Allergy Clin Immunol. 2006;117:466–8.
pubmed: 16461151 doi: 10.1016/j.jaci.2005.10.020
Joint Task Force on Practice Parameters, American Academy of Allergy, Asthma and Immunology, American College of Allergy, Asthma and Immunology, Joint Council of Allergy, Asthma and Immunology. Drug allergy: an updated practice parameter. Ann Allergy Asthma Immunol. 2010;105:259–73.
Sánchez-Borges M, Capriles-Hulett A. Atopy is a risk factor for non-steroidal anti-inflammatory drug sensitivity. Ann Allergy Asthma Immunol. 2000;84:101–6.
pubmed: 10674573 doi: 10.1016/S1081-1206(10)62748-2
Hassani A, Ponvert C, Karila C, Le Bourgeois M, De Blic J, Scheinmann P. Hypersensitivity to cyclooxygenase inhibitory drugs in children: a study of 164 cases. Eur J Dermatol. 2008;18:561–5.
pubmed: 18693161
Quiralte J, Blanco C, Delgado J, Ortega N, Alcntára M, Castillo R, et al. Challenge-based clinical patterns of 223 Spanish patients with nonsteroidal anti-inflammatory-drug-induced-reactions. J Investig Allergol Clin Immunol. 2007;17:182–8.
pubmed: 17583106
Ponvert C. Scheinmann P [Allergic and pseudoallergic reactions to analgesics, antipyretics and non-steroidal anti-inflammatory drugs]. Arch Pediatr. 2007;14:507–12.
pubmed: 17442550 doi: 10.1016/j.arcped.2007.03.009
Kidon MI, Kang LW, Chin CW, Hoon LS, See Y, Goh A, et al. Early presentation with angioedema and urticaria in cross-reactive hypersensitivity to nonsteroidal antiinflammatory drugs among young, Asian, atopic children. Pediatrics. 2005;116:e675-680.
pubmed: 16230465 doi: 10.1542/peds.2005-0969
Ayuso P, Blanca-López N, Doña I, Torres MJ, Guéant-Rodríguez RM, Canto G, et al. Advanced phenotyping in hypersensitivity drug reactions to NSAIDs. Clin Exp Allergy. 2013;43:1097–109.
pubmed: 24074328 doi: 10.1111/cea.12140
Lo P-C, Tsai Y-T, Lin S-K, Lai J-N. Risk of asthma exacerbation associated with nonsteroidal anti-inflammatory drugs in childhood asthma: A nationwide population-based cohort study in Taiwan. Medicine (Baltimore). 2016;95:e5109.
pubmed: 27741128 doi: 10.1097/MD.0000000000005109
Sánchez-Borges M, Caballero-Fonseca F, Capriles-Hulett A. Cofactors and comorbidities in patients with aspirin/NSAID hypersensitivity. Allergol Immunopathol (Madr). 2016;S0301–0546:30121–5.
Asero R. Single NSAID hypersensitivity is associated with atopic status. Eur Ann Allergy Clin Immunol. 2015;47:48–53.
pubmed: 25781194
Blanca-López N, Cornejo-García JA, Plaza-Serón MC, Doña I, Torres-Jaén MJ, Canto G, et al. Hypersensitivity to Nonsteroidal Anti-inflammatory Drugs in Children and Adolescents: Cross-Intolerance Reactions. J Investig Allergol Clin Immunol. 2015;25:259–69.
pubmed: 26310040
Zambonino MA, Torres MJ, Muñoz C, Requena G, Mayorga C, Posadas T, et al. Drug provocation tests in the diagnosis of hypersensitivity reactions to non-steroidal anti-inflammatory drugs in children. Pediatr Allergy Immunol. 2013;24:151–9.
pubmed: 23506290 doi: 10.1111/pai.12039
Arikoglu T, Aslan G, Yildirim DD, Batmaz SB, Kuyucu S. Discrepancies in the diagnosis and classification of nonsteroidal anti-inflammatory drug hypersensitivity reactions in children. Allergol Int. 2016;S1323–8930:30158–67.
Alves C, Romeira AM, Abreu C, Carreiro-Martins P, Gomes E, Leiria-Pinto P. Non-steroidal anti-inflammatory drug hypersensitivity in children. Allergol Immunopathol (Madr). 2017;45:40–7.
pubmed: 27475775 doi: 10.1016/j.aller.2016.04.004
Tsabouri S, Arasi S, Beken B, Church MK, Alvaro-Lozano M, Caffarelli C, et al. A European survey of management approaches in chronic urticaria in children: EAACI pediatric urticaria taskforce. Pediatr Allergy Immunol. 2022;33: e13674.
pubmed: 34601755 doi: 10.1111/pai.13674
Ponvert C, Perrin Y, Bados-Albiero A, Le Bourgeois M, Karila C, Delacourt C, et al. Allergy to betalactam antibiotics in children: results of a 20-year study based on clinical history, skin and challenge tests. Pediatr Allergy Immunol. 2011;22:411–8.
pubmed: 21535179 doi: 10.1111/j.1399-3038.2011.01169.x
Tugcu GD, Cavkaytar O, Sekerel BE, Sackesen C, Kalayci O, Tuncer A, et al. Actual drug allergy during childhood: Five years’ experience at a tertiary referral centre. Allergol Immunopathol (Madr). 2015;43:571–8.
pubmed: 25963806 doi: 10.1016/j.aller.2015.01.005
Indradat S, Veskitkul J, Pacharn P, Jirapongsananuruk O, Visitsunthorn N. Provocation proven drug allergy in Thai children with adverse drug reactions. Asian Pac J Allergy Immunol. 2016;34:59–64.
pubmed: 26994627
Demirhan A, Yildirim DD, Arikoglu T, Ozhan AK, Tokmeci N, Yuksek BC, et al. A combined risk modeling strategy for clinical prediction of beta-lactam allergies in children. Allergy Asthma Proc. 2021;42:e159–66.
pubmed: 34871164 doi: 10.2500/aap.2021.42.210068
Wu P, Longbottom K, Hague R, Vance G. Fifteen-minute consultation: A child with a suspected drug allergy. Arch Dis Child Educ Pract Ed. 2018;103:124–30.
pubmed: 29122832 doi: 10.1136/archdischild-2016-311188
Sharma VK, Dhar S. Clinical pattern of cutaneous drug eruption among children and adolescents in north India. Pediatr Dermatol. 1995;12:178–83.
pubmed: 7659648 doi: 10.1111/j.1525-1470.1995.tb00149.x
Mill C, Primeau M-N, Medoff E, Lejtenyi C, O’Keefe A, Netchiporouk E, et al. Assessing the Diagnostic Properties of a Graded Oral Provocation Challenge for the Diagnosis of Immediate and Nonimmediate Reactions to Amoxicillin in Children. JAMA Pediatr. 2016;170:e160033.
pubmed: 27043788 doi: 10.1001/jamapediatrics.2016.0033
Chung W-H, Hung S-I, Hong H-S, Hsih M-S, Yang L-C, Ho H-C, et al. Medical genetics: a marker for Stevens-Johnson syndrome. Nature. 2004;428:486.
pubmed: 15057820 doi: 10.1038/428486a
Locharernkul C, Loplumlert J, Limotai C, Korkij W, Desudchit T, Tongkobpetch S, et al. Carbamazepine and phenytoin induced Stevens-Johnson syndrome is associated with HLA-B*1502 allele in Thai population. Epilepsia. 2008;49:2087–91.
pubmed: 18637831 doi: 10.1111/j.1528-1167.2008.01719.x
Mehta TY, Prajapati LM, Mittal B, Joshi CG, Sheth JJ, Patel DB, et al. Association of HLA-B*1502 allele and carbamazepine-induced Stevens-Johnson syndrome among Indians. Indian J Dermatol Venereol Leprol. 2009;75:579–82.
pubmed: 19915237 doi: 10.4103/0378-6323.57718
Kaniwa N, Saito Y, Aihara M, Matsunaga K, Tohkin M, Kurose K, et al. HLA-B locus in Japanese patients with anti-epileptics and allopurinol-related Stevens-Johnson syndrome and toxic epidermal necrolysis. Pharmacogenomics. 2008;9:1617–22.
pubmed: 19018717 doi: 10.2217/14622416.9.11.1617
McCormack M, Alfirevic A, Bourgeois S, Farrell JJ, Kasperavičiūtė D, Carrington M, et al. HLA-A*3101 and carbamazepine-induced hypersensitivity reactions in Europeans. N Engl J Med. 2011;364:1134–43.
pubmed: 21428769 pmcid: 3113609 doi: 10.1056/NEJMoa1013297
Ramírez E, Bellón T, Tong HY, Borobia AM, de Abajo FJ, Lerma V, et al. Significant HLA class I type associations with aromatic antiepileptic drug (AED)-induced SJS/TEN are different from those found for the same AED-induced DRESS in the Spanish population. Pharmacol Res. 2017;115:168–78.
pubmed: 27888155 doi: 10.1016/j.phrs.2016.11.027
Asif BA, Koh C, Phillips EJ, Gu J, Li YJ, Barnhart H, et al. Vancomycin-induced liver injury, DRESS, and HLA-A*32:01. J Allergy Clin Immunol Pract. 2024;12:168-174.e2.
pubmed: 37739311 doi: 10.1016/j.jaip.2023.09.011
Man CBL, Kwan P, Baum L, Yu E, Lau KM, Cheng ASH, et al. Association between HLA-B*1502 allele and antiepileptic drug-induced cutaneous reactions in Han Chinese. Epilepsia. 2007;48:1015–8.
pubmed: 17509004 doi: 10.1111/j.1528-1167.2007.01022.x
Hung S-I, Chung W-H, Liou L-B, Chu C-C, Lin M, Huang H-P, et al. HLA-B*5801 allele as a genetic marker for severe cutaneous adverse reactions caused by allopurinol. Proc Natl Acad Sci U S A. 2005;102:4134–9.
pubmed: 15743917 pmcid: 554812 doi: 10.1073/pnas.0409500102
Lonjou C, Thomas L, Borot N, Ledger N, de Toma C, LeLouet H, et al. A marker for Stevens-Johnson syndrome …: ethnicity matters. Pharmacogenomics J. 2006;6:265–8.
pubmed: 16415921 doi: 10.1038/sj.tpj.6500356
Tassaneeyakul W, Jantararoungtong T, Chen P, Lin P-Y, Tiamkao S, Khunarkornsiri U, et al. Strong association between HLA-B*5801 and allopurinol-induced Stevens-Johnson syndrome and toxic epidermal necrolysis in a Thai population. Pharmacogenet Genomics. 2009;19:704–9.
pubmed: 19696695 doi: 10.1097/FPC.0b013e328330a3b8
Mallal S, Nolan D, Witt C, Masel G, Martin AM, Moore C, et al. Association between presence of HLA-B*5701, HLA-DR7, and HLA-DQ3 and hypersensitivity to HIV-1 reverse-transcriptase inhibitor abacavir. Lancet. 2002;359:727–32.
pubmed: 11888582 doi: 10.1016/S0140-6736(02)07873-X
Hughes AR, Mosteller M, Bansal AT, Davies K, Haneline SA, Lai EH, et al. Association of genetic variations in HLA-B region with hypersensitivity to abacavir in some, but not all, populations. Pharmacogenomics. 2004;5:203–11.
pubmed: 15016610 doi: 10.1517/phgs.5.2.203.27481
Park WB, Choe PG, Song K-H, Lee S, Jang H-C, Jeon JH, et al. Should HLA-B*5701 screening be performed in every ethnic group before starting abacavir? Clin Infect Dis. 2009;48:365–7.
pubmed: 19115972 doi: 10.1086/595890
Mallal S, Phillips E, Carosi G, Molina J-M, Workman C, Tomazic J, et al. HLA-B*5701 screening for hypersensitivity to abacavir. N Engl J Med. 2008;358:568–79.
pubmed: 18256392 doi: 10.1056/NEJMoa0706135
Amstutz U, Shear NH, Rieder MJ, Hwang S, Fung V, Nakamura H, et al. Recommendations for HLA-B*15:02 and HLA-A*31:01 genetic testing to reduce the risk of carbamazepine-induced hypersensitivity reactions. Epilepsia. 2014;55:496–506.
pubmed: 24597466 doi: 10.1111/epi.12564
Ferrell PB, McLeod HL. Carbamazepine, HLA-B*1502 and risk of Stevens-Johnson syndrome and toxic epidermal necrolysis: US FDA recommendations. Pharmacogenomics. 2008;9:1543–6.
pubmed: 18855540 doi: 10.2217/14622416.9.10.1543
Nuki G. An appraisal of the 2012 American College of Rheumatology Guidelines for the Management of Gout. Curr Opin Rheumatol. 2014;26:152–61.
pubmed: 24492863 doi: 10.1097/BOR.0000000000000034
Saokaew S, Tassaneeyakul W, Maenthaisong R, Chaiyakunapruk N. Cost-effectiveness analysis of HLA-B*5801 testing in preventing allopurinol-induced SJS/TEN in Thai population. PLoS ONE. 2014;9:e94294.
pubmed: 24732692 pmcid: 3986079 doi: 10.1371/journal.pone.0094294
Khan DA, Banerji A, Blumenthal KG, Phillips EJ, Solensky R, White AA, et al. Drug allergy: A 2022 practice parameter update. J Allergy Clin Immunol. 2022;150:1333–93.
pubmed: 36122788 doi: 10.1016/j.jaci.2022.08.028
Cornejo-Garcia JA, Oussalah A, Blanca M, Gueant-Rodriguez R-M, Mayorga C, Waton J, et al. Genetic Predictors of Drug Hypersensitivity. Curr Pharm Des. 2016;22:6725–33.
pubmed: 27779086 doi: 10.2174/1381612822666160927114941
Karlin E, Phillips E. Genotyping for severe drug hypersensitivity. Curr Allergy Asthma Rep. 2014;14:418.
pubmed: 24429903 pmcid: 4014135 doi: 10.1007/s11882-013-0418-0
Urban TJ, Daly AK, Aithal GP. Genetic basis of drug-induced liver injury: present and future. Semin Liver Dis. 2014;34:123–33.
pubmed: 24879978 doi: 10.1055/s-0034-1375954
Guéant J-L, Romano A, Cornejo-Garcia J-A, Oussalah A, Chery C, Blanca-López N, et al. HLA-DRA variants predict penicillin allergy in genome-wide fine-mapping genotyping. J Allergy Clin Immunol. 2015;135:253–9.
pubmed: 25224099 doi: 10.1016/j.jaci.2014.07.047
Fernandez CA, Smith C, Yang W, Mullighan CG, Qu C, Larsen E, et al. Genome-wide analysis links NFATC2 with asparaginase hypersensitivity. Blood. 2015;126:69–75.
pubmed: 25987655 pmcid: 4492197 doi: 10.1182/blood-2015-02-628800
Liu S, Gao C, Wu Y, Lin W, Li J, Xue T, et al. HLA-DRB1*16:02 is associated with PEG-asparaginase hypersensitivity. Pharmacogenomics. 2021;22:1135–42.
pubmed: 34747637 doi: 10.2217/pgs-2021-0107
Agúndez JAG, Mayorga C, García-Martin E. Drug metabolism and hypersensitivity reactions to drugs. Curr Opin Allergy Clin Immunol. 2015;15:277–84.
pubmed: 26110676 doi: 10.1097/ACI.0000000000000174
Lee A-Y, Kim M-J, Chey W-Y, Choi J, Kim B-G. Genetic polymorphism of cytochrome P450 2C9 in diphenylhydantoin-induced cutaneous adverse drug reactions. Eur J Clin Pharmacol. 2004;60:155–9.
pubmed: 15024534 doi: 10.1007/s00228-004-0753-0
Clayton TA, Lindon JC, Cloarec O, Antti H, Charuel C, Hanton G, et al. Pharmaco-metabonomic phenotyping and personalized drug treatment. Nature. 2006;440:1073–7.
pubmed: 16625200 doi: 10.1038/nature04648
Lavergne SN, Park BK, Naisbitt DJ. The roles of drug metabolism in the pathogenesis of T-cell-mediated drug hypersensitivity. Curr Opin Allergy Clin Immunol. 2008;8:299–307.
pubmed: 18596585 doi: 10.1097/ACI.0b013e3283079c64
Martínez C, Andreu I, Amo G, Miranda MA, Esguevillas G, Torres MJ, et al. Gender and functional CYP2C and NAT2 polymorphisms determine the metabolic profile of metamizole. Biochem Pharmacol. 2014;92:457–66.
pubmed: 25241292 doi: 10.1016/j.bcp.2014.09.005
García-Martín E, Esguevillas G, Blanca-López N, García-Menaya J, Blanca M, Amo G, et al. Genetic determinants of metamizole metabolism modify the risk of developing anaphylaxis. Pharmacogenet Genomics. 2015;25:462–4.
pubmed: 26111152 doi: 10.1097/FPC.0000000000000157
Huang Y-S, Chern H-D, Su W-J, Wu J-C, Chang S-C, Chiang C-H, et al. Cytochrome P450 2E1 genotype and the susceptibility to antituberculosis drug-induced hepatitis. Hepatology. 2003;37:924–30.
pubmed: 12668988 doi: 10.1053/jhep.2003.50144
Kim S-H, Kim S-H, Bahn J-W, Kim Y-K, Chang Y-S, Shin E-S, et al. Genetic polymorphisms of drug-metabolizing enzymes and anti-TB drug-induced hepatitis. Pharmacogenomics. 2009;10:1767–79.
pubmed: 19891553 doi: 10.2217/pgs.09.100
Kim S-H, Kim S-H, Yoon HJ, Shin DH, Park SS, Kim Y-S, et al. NAT2, CYP2C9, CYP2C19, and CYP2E1 genetic polymorphisms in anti-TB drug-induced maculopapular eruption. Eur J Clin Pharmacol. 2011;67:121–7.
pubmed: 20941486 doi: 10.1007/s00228-010-0912-4
Doña I, Torres MJ, Celik G, Phillips E, Tanno LK, Castells M. Changing patterns in the epidemiology of drug allergy. Allergy. 2024;79:613–28.
pubmed: 38084822 doi: 10.1111/all.15970
Whitaker P, Naisbitt D, Peckham D. Nonimmediate β-lactam reactions in patients with cystic fibrosis. Curr Opin Allergy Clin Immunol. 2012;12:369–75.
pubmed: 22729028 doi: 10.1097/ACI.0b013e328355b849
Caimmi S, Sanfiorenzo C, Caimmi D, Bousquet P-J, Chiron R, Demoly P. Comprehensive allergy work-up is mandatory in cystic fibrosis patients who report a history suggestive of drug allergy to beta-lactam antibiotics. Clin Transl Allergy. 2012;2:10.
pubmed: 22697261 pmcid: 3441352 doi: 10.1186/2045-7022-2-10
Matar R, Le Bourgeois M, Scheinmann P, de Blic J, Ponvert C. Beta-lactam hypersensitivity in children with cystic fibrosis: a study in a specialized pediatric center for cystic fibrosis and drug allergy. Pediatr Allergy Immunol. 2014;25:88–93.
pubmed: 24237053 doi: 10.1111/pai.12154
Atanaskovic-Markovic M, Gomes E, Cernadas JR, du Toit G, Kidon M, Kuyucu S, et al. Diagnosis and management of drug-induced anaphylaxis in children: An EAACI position paper. Pediatr Allergy Immunol. 2019;30:269–76.
pubmed: 30734362 doi: 10.1111/pai.13034
Mori F, Crisafulli G, Bianchi A, Bottau P, Caimmi S, Franceschini F, et al. Drugs and vaccines hypersensitivity in children with mastocytosis. J Clin Med. 2022;11:3153.
pubmed: 35683540 pmcid: 9181546 doi: 10.3390/jcm11113153
Kuyucu S, Caubet J-C. Hypersensitivity reactions to antiepileptic drugs in children: Epidemiologic, pathogenetic, clinical, and diagnostic aspects. J Allergy Clin Immunol Pract. 2018;6:1879-1891.e1.
pubmed: 30104171 doi: 10.1016/j.jaip.2018.07.003
Shiohara T, Kano Y. A complex interaction between drug allergy and viral infection. Clin Rev Allergy Immunol. 2007;33:124–33.
pubmed: 18094951 doi: 10.1007/s12016-007-8010-9
Adam J, Pichler WJ, Yerly D. Delayed drug hypersensitivity: models of T-cell stimulation. Br J Clin Pharmacol. 2011;71:701–7.
pubmed: 21480949 pmcid: 3093075 doi: 10.1111/j.1365-2125.2010.03764.x
Caubet J-C, Kaiser L, Lemaître B, Fellay B, Gervaix A, Eigenmann PA. The role of penicillin in benign skin rashes in childhood: a prospective study based on drug rechallenge. J Allergy Clin Immunol. 2011;127:218–22.
pubmed: 21035175 doi: 10.1016/j.jaci.2010.08.025
Patel BM. Skin rash with infectious mononucleosis and ampicillin. Pediatrics. 1967;40:910–1.
pubmed: 6075667 doi: 10.1542/peds.40.5.910
Thompson DF, Ramos CL. Antibiotic-induced rash in patients with infectious mononucleosis. Ann Pharmacother. 2017;51:154–62.
pubmed: 27620494 doi: 10.1177/1060028016669525
Chovel-Sella A, Ben Tov A, Lahav E, Mor O, Rudich H, Paret G, et al. Incidence of rash after amoxicillin treatment in children with infectious mononucleosis. Pediatrics. 2013;131:e1424-1427.
pubmed: 23589810 doi: 10.1542/peds.2012-1575
Jappe U. Amoxicillin-induced exanthema in patients with infectious mononucleosis: allergy or transient immunostimulation? Allergy. 2007;62:1474–5.
pubmed: 17983386 doi: 10.1111/j.1398-9995.2007.01518.x
Ónodi-Nagy K, Kinyó Á, Meszes A, Garaczi E, Kemény L, Bata-Csörgő Z. Amoxicillin rash in patients with infectious mononucleosis: evidence of true drug sensitization. Allergy Asthma Clin Immunol. 2015;11:1.
pubmed: 25784943 pmcid: 4362637 doi: 10.1186/1710-1492-11-1
Chen Y-C, Chiang H-H, Cho Y-T, Chang C-Y, Chen K-L, Yang C-W, et al. Human herpes virus reactivations and dynamic cytokine profiles in patients with cutaneous adverse drug reactions –a prospective comparative study. Allergy. 2015;70:568–75.
pubmed: 25727950 doi: 10.1111/all.12602
Ozcan D, Seçkin D, Bilezikçi B, Arslan H. The role of human herpesvirus-6, Epstein-Barr virus and cytomegalovirus infections in the etiopathogenesis of different types of cutaneous drug reactions. Int J Dermatol. 2010;49:1250–4.
pubmed: 21038542 doi: 10.1111/j.1365-4632.2010.04531.x
Mori F, Caffarelli C, Caimmi S, Bottau P, Liotti L, Franceschini F, et al. Drug reaction with eosinophilia and systemic symptoms (DRESS) in children. Acta Biomed. 2019;90:66–79.
pubmed: 30830064
Hubiche T, Milpied B, Cazeau C, Taïeb A, Léauté-Labrèze C. Association of immunologically confirmed delayed drug reaction and human herpesvirus 6 viremia in a pediatric case of drug-induced hypersensitivity syndrome. Dermatology. 2011;222:140–1.
pubmed: 21389685 doi: 10.1159/000324506
Ravin KA, Rappaport LD, Zuckerbraun NS, Wadowsky RM, Wald ER, Michaels MM. Mycoplasma pneumoniae and atypical Stevens-Johnson syndrome: a case series. Pediatrics. 2007;119:e1002-1005.
pubmed: 17353300 doi: 10.1542/peds.2006-2401
Ahluwalia J, Wan J, Lee DH, Treat J, Yan AC. Mycoplasma-associated Stevens-Johnson syndrome in children: retrospective review of patients managed with or without intravenous immunoglobulin, systemic corticosteroids, or a combination of therapies. Pediatr Dermatol. 2014;31:664–9.
pubmed: 25424206 doi: 10.1111/pde.12481
Liotti L, Caimmi S, Bottau P, Bernardini R, Cardinale F, Saretta F, Mori F, Crisafulli G, Franceschini F, Caffarelli C. Clinical features, outcomes and treatment in children with drug induced Stevens-Johnson syndrome and toxic epidermal necrolysis. Acta Biomed. 2019;29(90):52–60.
Lofgren D, Lenkeit C. Mycoplasma Pneumoniae-induced rash and mucositis: A systematic review of the literature. Spartan Med Res J. 2021;6:25284.
pubmed: 34532621 pmcid: 8405277 doi: 10.51894/001c.25284
Phillips E, Mallal S. Drug hypersensitivity in HIV. Curr Opin Allergy Clin Immunol. 2007;7:324–30.
pubmed: 17620824 doi: 10.1097/ACI.0b013e32825ea68a
Knight L, Muloiwa R, Dlamini S, Lehloenya RJ. Factors associated with increased mortality in a predominantly HIV-infected population with Stevens Johnson syndrome and toxic epidermal necrolysis. PLoS ONE. 2014;9:e93543.
pubmed: 24695805 pmcid: 3973591 doi: 10.1371/journal.pone.0093543
Breen RA, Miller RF, Gorsuch T, et al. Adverse events and treatment interruption in tuberculosis patients with and without HIV co-infection. Thorax. 2006;61:791–4.
pubmed: 16844730 pmcid: 2117099 doi: 10.1136/thx.2006.058867
Saka B, Barro-Traoré F, Atadokpédé FA, Kobangue L, Niamba PA, Adégbidi H, et al. Stevens-Johnson syndrome and toxic epidermal necrolysis in sub-Saharan Africa: a multicentric study in four countries. Int J Dermatol. 2013;52:575–9.
pubmed: 23330601 doi: 10.1111/j.1365-4632.2012.05743.x
Adegbidi H, Atadokpede F, Sagbo G, et al. Drug eruptions in children in Cotonou. Benin Mali Med. 2012;27:42–6.
pubmed: 22947321
Coopman SA, Johnson RA, Platt R, Stern RS. Cutaneous disease and drug reactions in HIV infection. N Engl J Med. 1993;328:1670–4.
pubmed: 8487826 doi: 10.1056/NEJM199306103282304
Chanock SJ, Luginbuhl LM, McIntosh K, Lipshultz SE. Life-threatening reaction to trimethoprim/sulfamethoxazole in pediatric human immunodeficiency virus infection. Pediatrics. 1994;93:519–21.
pubmed: 8115221 doi: 10.1542/peds.93.3.519
Moral L, Roig M, Toral T, Fuentes MJ, Martos MD, Garde J. Alergia a antibióticos betalactámicos en una población pediátrica: descripción de una serie amplia. Allergol Immunopathol. 2008;36(Suppl 1):62–73.
Moral L, Garde J, Toral T, Fuentes MJ, Marco N. Short protocol for the study of paediatric patients with suspected betalactam antibiotic hypersensitivity and low risk criteria. Allergol Immunopathol (Madr). 2011;39:337–41.
pubmed: 21429652 doi: 10.1016/j.aller.2010.10.002
Zambonino MA, Corzo JL, Munoz C, Requena G, Ariza A, Mayorga C, et al. Diagnostic evaluation of hyper- sensitivity reactions to beta-lactam antibiotics in a large population of children. Pediatr Allergy Immunol. 2014;25:80–7.
pubmed: 24329898 doi: 10.1111/pai.12155
Blanca-Lopez N, Cornejo JA, Perez-Sanchez NI, et al. Hypersensitivity reactions to NSAIDs in children. J Allergy Clin Immunol. 2017;139:34.
doi: 10.1016/j.jaci.2016.12.169
Topal E, Celiksoy MH, Catal F, Gamze Sayan Y, Sancak R. The value of the clinical history for the diagnosis of immediate nonsteroidal anti-inflammatory drug hypersensitivity and safe alternative drugs in children. Allergy Asthma Proc. 2016;37:57–63.
pubmed: 26831848 doi: 10.2500/aap.2016.37.3917
Caffarelli C, Franceschini F, Caimmi D, Mori F, Diaferio L, Di Mauro D, et al. SIAIP position paper: provocation challenge to antibiotics and non-steroidal anti-inflammatory drugs in children. Ital J Pediatr. 2018;44:147.
pubmed: 30526636 pmcid: 6286516 doi: 10.1186/s13052-018-0589-3
Sipahi Cimen S, Hizli Demirkale Z, Yucel E, Ozceker D, Suleyman A, Sayili U, et al. Risk factors of challenge-proven beta-lactam allergy in children with immediate and non-immediate mild cutaneous reactions. Int Arch Allergy Immunol. 2023;184:539–49.
pubmed: 36858038 doi: 10.1159/000529084
Vorobeichik L, Weber EA, Tarshis J. Misconceptions surrounding penicillin allergy: Implications for anesthesiologists. Anesth Analg. 2018;127:642–9.
pubmed: 29757781 doi: 10.1213/ANE.0000000000003419
Cavkaytar O, Karaatmaca B, Arik Yilmaz E, Sahiner UM, Sackesen C, Sekerel BE, et al. Basal serum tryptase is not a risk factor for immediate-type drug hypersensitivity during childhood. Pediatr Allergy Immunol. 2016;27:736–42.
pubmed: 27288661 doi: 10.1111/pai.12604
Chiriac AM, Wang Y, Schrijvers R, Bousquet PJ, Mura T, Molinari N, et al. Designing predictive models for beta-lactam allergy using the drug allergy and hypersensitivity database. J Allergy Clin Immunol Pract. 2018;6:139-148.e2.
pubmed: 28739365 doi: 10.1016/j.jaip.2017.04.045
Romano A, Valluzzi RL, Caruso C, Maggioletti M, Quaratino D, Gaeta F. Cross-Reactivity and Tolerability of Cephalosporins in Patients with IgE-Mediated Hypersensitivity to Penicillins. J Allergy Clin Immunol Pract. 2018;6:1662–72.
pubmed: 29408440 doi: 10.1016/j.jaip.2018.01.020
Chiriac A-M, Rerkpattanapipat T, Bousquet P-J, Molinari N, Demoly P. Optimal step doses for drug provocation tests to prove beta-lactam hypersensitivity. Allergy. 2017;72:552–61.
pubmed: 27569064 doi: 10.1111/all.13037
Stone CA, Trubiano J, Coleman DT, Rukasin CRF, Phillips EJ. The challenge of de-labeling penicillin allergy. Allergy. 2020;75:273–88.
pubmed: 31049971 doi: 10.1111/all.13848
Warrington R, Silviu-Dan F, Wong T. Drug allergy. Allergy Asthma. Clin Immunol. 2018;14(Suppl 2):60.
Impicciatore P, Choonara I, Clarkson A, Provasi D, Pandolfini C, Bonati M. Incidence of adverse drug reactions in paediatric in/out-patients: a systematic review and meta-analysis of prospective studies. Br J Clin Pharmacol. 2001;52:77–83.
pubmed: 11453893 pmcid: 2014499 doi: 10.1046/j.0306-5251.2001.01407.x
Gallagher RM, Mason JR, Bird KA, Kirkham JJ, Peak M, Williamson PR, et al. Adverse drug reactions causing admission to a paediatric hospital. PLoS ONE. 2012;7:e50127.
pubmed: 23226510 pmcid: 3514275 doi: 10.1371/journal.pone.0050127
Rashed AN, Wong ICK, Cranswick N, Tomlin S, Rascher W, Neubert A. Risk factors associated with adverse drug reactions in hospitalised children: international multicentre study. Eur J Clin Pharmacol. 2012;68:801–10.
pubmed: 22166934 doi: 10.1007/s00228-011-1183-4
Summers CW, Pumphrey RS, Woods CN, McDowell G, Pemberton PW, Arkwright PD. Factors predicting anaphylaxis to peanuts and tree nuts in patients referred to a specialist center. J Allergy Clin Immunol. 2008;12:632-638.e2.
doi: 10.1016/j.jaci.2007.12.003
Lalic M, Cvejic J, Popovic J, Bozic K, Golocorbin-Kon S, Al-Salami H, et al. Lamotrigine and valproate pharmacokinetics interactions in epileptic patients. Eur J Drug Metab Pharmacokinet. 2009;34:93–9.
pubmed: 19645218 doi: 10.1007/BF03191157
Choed-Amphai C, Khorana J, Sathitsamitphong L, Natesirinilkul R, Charoenkwan P. Predictive factors for L-asparaginase hypersensitivity in pediatric acute lymphoblastic leukemia. Int J Hematol. 2024;119:442–9.
pubmed: 38421487 doi: 10.1007/s12185-024-03725-z
Kugathasan S, Levy MB, Saeian K, Vasilopoulos S, Kim JP, Prajapati D, et al. Infliximab retreatment in adults and children with Crohn’s disease: risk factors for the development of delayed severe systemic reaction. Am J Gastroenterol. 2002;97:1408–14.
pubmed: 12094858 doi: 10.1111/j.1572-0241.2002.05784.x
Bianchi A, Valluzzi R, Crisafulli G, Bottau P, Caimmi S, Franceschini F, Liotti L, Mori F, Riscassi S, Saretta F, Scavone S, Caffarelli C. Drug-induced anaphylaxis in children Biomedicines. 2024;12:527.
pubmed: 38540140
Blumenthal KG. The role of the clinical history in drug allergy prediction. J Allergy Clin Immunol Pract. 2018;6:149–50.
pubmed: 29310757 doi: 10.1016/j.jaip.2017.05.005
Exius R, Gabrielli S, Abrams EM, O’Keefe A, Protudjer JLP, Lavine E, et al. Establishing amoxicillin allergy in children through direct graded oral challenge (GOC): Evaluating risk factors for positive challenges, safety, and risk of cross-reactivity to cephalosporines. J Allergy Clin Immunol Pract. 2021;9:4060–6.
pubmed: 34293504 doi: 10.1016/j.jaip.2021.06.057
Kowalic A, de Monestrol I, Sorjonen K, Brockow K, Gulen T. Antibiotic hypersensitivity in cystic fibrosis- Low frequency of anaphylaxis over 16000 courses. Br J Clin Pharmacol. 2022;88:4845–53.
doi: 10.1111/bcp.15434

Auteurs

Francesca Mori (F)

Allergy Unit, Meyer Children's Hospital IRCCS, 50139, Florence, Italy.

Francesca Saretta (F)

Dipartimento Materno-Infantile, SC Pediatria, Ospedale Latisana-Palmanova, Azienda Sanitaria Universitaria Friuli Centrale, 33100, Udine, Italy.

Sara Riscassi (S)

UOC Di Pediatria, Ospedale Bolzano, Azienda Sanitaria Dell'Alto Adige, Bolzano, 39100, Italy.

Silvia Caimmi (S)

SC Di Pediatria, Fondazione IRCSS Policlinico San Matteo, 27100, Pavia, Italy.

Paolo Bottau (P)

UOC Di Pediatria E Neonatologia, Ospedale Imola (BO), Imola, 40026, Italy.

Lucia Liotti (L)

UOC Pediatria, Azienda Ospedaliero-Universitaria "Ospedali Riuniti", 60100, Ancona, Italy.

Fabrizio Franceschini (F)

Private Practice in Allergy, 60100, Ancona, Italy.

Annamaria Bianchi (A)

UOC Pediatria, Azienda Ospedaliera San Camillo Forlanini, 00152, Rome, Italy.

Rocco Luigi Valluzzi (RL)

Translational Research in Pediatric Specialties Area, Division of Allergy, Bambino Gesù Children's Hospital, IRCCS, 00165, Rome, Italy.

Giuseppe Crisafulli (G)

Dipartimento Materno-Infantile, UOC Pediatria, University of Messina, Messina, 98122, Italy.

Carlo Caffarelli (C)

Department of Medicine and Surgery, Clinica Pediatrica, Azienda Ospedaliera-Universitaria, University of Parma, 43123, Parma, Italy. carlo.caffarelli@gmail.com.
ORCID: 0000-0001-7710-6995

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female

Evaluation of Low-Value Services Across Major Medicare Advantage Insurers and Traditional Medicare.

Ciara Duggan, Adam L Beckman, Ishani Ganguli et al.
1.00
Humans United States Aged Cross-Sectional Studies Medicare Part C

Effectiveness of Virtual Yoga for Chronic Low Back Pain: A Randomized Clinical Trial.

Hallie Tankha, Devyn Gaskins, Amanda Shallcross et al.
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH

questionsmedicales.fr › Eucaryotes › Animaux › Chordés › Vertébrés › Mammifères › Eutheria › Primates › Haplorhini › Catarrhini › Hominidae › Humains › Risk factors for drug hypersensitivity...
questionsmedicales.fr › Environnement et santé publique › Santé publique › Méthodes épidémiologiques › Statistiques comme sujet › Probabilité › Risque › Facteurs de risque › Risk factors for drug hypersensitivity...
questionsmedicales.fr › Personnes › Tranches d'âge › Enfant › Risk factors for drug hypersensitivity...
questionsmedicales.fr › Troubles dus à des produits chimiques › Effets secondaires indésirables des médicaments › Hypersensibilité médicamenteuse › Risk factors for drug hypersensitivity...